c-Met is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-03-02. Numbers and descriptions here follow the published literature rather than marketing material.
Dihexa is not approved for human use in the United States or the European Union. It is commonly sold as a research chemical, a category that may not require the same regulatory review as medicines. Buyers should note that product labels may lack independent verification of identity or purity. The legal status can vary by country, and importation may be restricted. Reliable information about sourcing and quality is often scarce. Scientific publications typically use synthesized material from laboratories rather than commercial consumer products.
Dihexa is a synthetic peptide studied in laboratory research. It is often described as an angiotensin IV analog or a hepatocyte growth factor mimetic. The compound emerged from investigations into angiotensin IV and its effects on neural pathways. It is not an approved medication, and controlled human trials are lacking. In literature and online forums, it is discussed mainly as a research chemical. Its chemical name appears as N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) in some sources.
Early laboratory work focused on its effects on synaptic connectivity and neuronal signaling. In cell and animal models, dihexa has been reported to promote the formation of new synapses, a process called synaptogenesis. These findings have generated interest in cognitive research, but the evidence base remains mostly preclinical. Human clinical trials with clear safety and efficacy endpoints are limited or absent in the public literature. Whether these effects translate to humans is an open question.
The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.
| Property | Value | Notes |
|---|---|---|
| CAS Registry Number | 1401708-83-5 | Identifier used in chemical databases. |
| Common synonyms | P21; N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) | Names vary by supplier and publication. |
| Physical form | White to off-white powder | Lyophilized solid typical of peptides. |
| Solubility | Soluble in DMSO; limited in water | Aqueous preparation may need a co-solvent. |
| Storage | -20 °C, desiccated, protected from light | Reduce freeze-thaw cycles to maintain stability. |
Discussion in the literature often separates direct receptor activation from downstream growth-factor modulation. Dihexa is not simply an angiotensin receptor blocker or a classic nootropic drug. Its proposed action may depend on endogenous HGF levels, which vary by tissue and physiological state. Questions remain about brain penetration, metabolic stability, and active metabolites. Reviews note that mechanistic claims should be treated as hypotheses until supported by independent studies. That distinction is important when interpreting promotional claims or early laboratory findings.
The leading hypothesis for dihexa centers on hepatocyte growth factor (HGF) and its receptor, c-Met. In cell-based assays, dihexa has been reported to potentiate HGF-dependent signaling. That pathway influences cell growth, survival, and motility. Because c-Met signaling is widespread, the proposed mechanism is broad rather than specific to neurons. The exact binding site and stoichiometry remain areas of active investigation, and independent replication is limited. This uncertainty limits firm conclusions about how the compound acts in living organisms.
Quality control usually combines reverse-phase high-performance liquid chromatography with mass spectrometry. Chromatography estimates purity and detects related impurities, while mass spectrometry supports molecular identity. Nuclear magnetic resonance can provide additional structural confirmation when needed. Stability data for dihexa are limited, and degradation pathways may depend on pH, temperature, and moisture. Open questions include long-term stability in different formulations and the effect of repeated freeze-thaw cycles on measured purity. Such tests help confirm that a batch matches its label before use.
In laboratory settings, dihexa is typically handled as a lyophilized peptide powder. Appropriate personal protective equipment and a ventilated workspace are standard practices for weighing and transferring research chemicals. Because the compound lacks regulatory approval for clinical use, it should not be given to people. Institutional safety rules and local regulations govern its acquisition, storage, and disposal. Suppliers often provide a certificate of analysis that lists purity, identity, and batch-specific handling notes.
Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.
Dihexa is a synthetic peptide studied in preclinical neuroscience. It is often described as an angiotensin IV analog or derivative. The compound also appears under research codes such as PNB-0408 and N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. It is not an approved drug, and it is not a conventional vitamin or nutrient. In many jurisdictions, material sold as dihexa is handled as a research chemical rather than a medicine or supplement. This classification affects how the material is labeled and distributed.
Chemically, dihexa is a short peptide-like molecule with nonstandard components. Its structure includes tyrosine and isoleucine residues linked to a hexanoic acid group and an aminohexanoic amide segment. This design distinguishes it from endogenous angiotensin IV, though the two are discussed together because of shared origins. Published summaries classify it as a small synthetic peptide with lipophilic features that may influence how it crosses biological barriers in experimental systems. Exact conformational details depend on the specific salt or free base form.
Human safety data are sparse. No widely accepted dosing regimen, long-term safety profile, or clinical efficacy endpoint has been established. Published animal results can suggest directions for further study, but species differences and study design limit direct translation. Open questions include bioavailability, blood-brain barrier penetration, metabolism, and whether observed effects arise from a single target or multiple pathways. Replication across independent laboratories remains an important benchmark for evaluating the strength of preclinical claims.
Most published reports on dihexa come from cell cultures and animal models. Studies have examined markers of synapse formation, dendritic spine density, and performance on learning tasks in rodents. Proposed mechanisms center on hepatocyte growth factor and its c-Met receptor, with additional attention to angiotensin IV-related pathways. These findings are experimental and have not been confirmed as clinical benefits in humans. The literature often uses different tasks and endpoints, which complicates direct comparison across studies.
Regulatory status differs by country, but dihexa is generally not approved as a therapeutic product. It is often sold as a research chemical, which means purity, labeling, and handling fall outside pharmaceutical drug standards. Some jurisdictions restrict the sale of peptides intended for human consumption. Researchers and suppliers may therefore face different legal requirements depending on location. Import rules and customs enforcement can also affect how such compounds move across borders.
It is frequently used to package items that must remain cold or frozen, such as ice cream or biological samples, in the absence of availability or practicality of mechanical cooling. Dry ice is widely used in pharmaceutical cold-chain logistics, including the transportation of vaccines, biological samples, and temperature-sensitive medical products, which require storage at ultra-cold temperatures along their supply line. Dry ice can be used to flash-freeze food or laboratory biological samples, carbonate beverages, make ice cream, solidify oil spills and stop ice sculptures and ice walls from melting. Dry ice can be used to arrest and prevent insect activity in closed containers of grains and grain products, as it displaces oxygen, but does not alter the taste or quality of foods. For the same reason, it can prevent or retard food oils and fats from becoming rancid. When dry ice is placed in water, sublimation is accelerated, and low-sinking, dense clouds of smoke-like fog are created. This is used in fog machines, at theatres, haunted house attractions, and nightclubs for dramatic effects. Unlike most artificial fog machines, in which fog rises like smoke, fog from dry ice hovers near the ground. Dry ice is useful in theatre productions that require dense fog effects. The fog originates from the bulk water into which the dry ice is placed, and not from atmospheric water vapor (as is commonly assumed). It is occasionally used to freeze and remove warts.
A variety of agents are added to sequester (deactivate) metal ions that otherwise catalyze the oxidation of fats. Common sequestering agents are disodium EDTA, citric acid (and citrates), tartaric acid, and lecithin.
The witch doctor drinks a very small amount each time and knows well how many times he can sample the brew without losing his senses to properly conduct the ritual and lead the choir". Another report produced in 1737 by the missionary Pablo Maroni, describes the use of a psychoactive liana called ayahuasca for divination in the Napo River, Ecuador: "For divination, they use a beverage, some of white datura flowers, which they also call Campana due to its shape, and others from a vine commonly known as Ayahuasca, both highly effective at numbing the senses and even at taking one's life if taken in excess. They also occasionally use these substances for the treatment of common illnesses, especially headaches. So, the person who wants to divine drinks the chosen substance with certain rituals, and while deprived of their senses from the mouth downwards, to prevent the strength of the plant from harming them, they remain in this state for many hours and sometimes even two or three days until the effects run their course, and the intoxication subsides. After this, they reflect on what their imagination revealed, which occasionally remains with them for delirium. This is what they consider accomplished and propagate as an oracle." Latter reports were produced by Juan Magnin in 1740, describing ayahuasca use as a medicinal plant by the "Jivaroan" peoples (called ayahuessa) and by Franz Xaver Veigl in 1768, that reports about several "dangerous plants", including a bitter liana used for precognition and sorcery.
== Structure == LH is a heterodimeric glycoprotein. Each monomeric unit is a glycoprotein molecule; one alpha and one beta subunit make the full, functional protein. Its structure is similar to that of the other glycoprotein hormones, follicle-stimulating hormone (FSH), thyroid-stimulating hormone (TSH), and human chorionic gonadotropin (hCG). The protein dimer contains 2 glycopeptidic subunits (labeled alpha- and beta- subunits) that are non-covalently associated:
Sources: en.wikipedia.org
== Audit == Surveillance is often achieved through audits which helps to identify gaps in practice, compliance to standards and guidelines and staff knowledge deficits. Data collection through audit supports governance and practice improvement, where the results can be used to consolidate practice or drive change as required. The TP plays an important role in auditing and reporting to the blood management committee (or equivalent) to develop locally agreed action plans to implement quality improvements arising from audits. The TP liaison role between departments and clinical specialties helps them to facilitate and manage improvements/change involving and engaging appropriate stakeholders. TPs participate in local, regional or national audits. Audit activities may include:
== Reactions == It dissolves in water to give a mildly alkaline solution. It is insoluble in acetone and alcohols. Ammonium bicarbonate decomposes above about 36 °C into ammonia, carbon dioxide, and water in an endothermic process and so causes a drop in the temperature of the water:
== External links == Insulin+receptor at the U.S. National Library of Medicine Medical Subject Headings (MeSH) Overview of all the structural information available in the PDB for UniProt: P06213 (Insulin receptor) at the PDBe-KB.
== Bibliography == Cécile Allegri, Claire Brosse, Federico Oldenburg and Hervé Robert, La Pomme de terre, saveurs méditerranéennes, Éditions du Bottin Gourmand, coll. « Les essentiels du goût », 2003, 99 p. (ISBN 2-913306-61-6). Joseph Bonjean, Monographie de la pomme de terre envisagée dans ses rapports agricoles, scientifiques et industriels et comprenant l'histoire générale de la maladie des pommes de terre en 1845, Paris, Germer Baillière, 1846, 306 p. Collective, La Pomme de terre. Histoire et recettes gourmandes, Grenoble, Glénat, 2009, 160 p. (ISBN 2-7234-7319-8). Collective, La Pomme de terre, un tour du Monde en 200 recettes, Geneva, United Nations, 2008, 360 p. (ISBN 92-1-200373-7). Lucienne Desnoues, Toute la pomme de terre, Paris, Mercure de France, 1978, 302 p. Qu Dongyu et Xie Kaiyun, How the Chinese Eat Potatoes, Singapour, World Scientific Publishing Company, 2009, 432 p. (ISBN 981-283-291-2). Jean Ferniot (pref. Joël Robuchon), Chère pomme de terre, First, 1996, 301 p. (ISBN 978-2-87691-327-1). Martine Jolly, Merci M. Parmentier, ou La gloire de la pomme de terre en 200 recettes, Robert Laffont, 1985, 224 p. (ISBN 2-221-04653-6). Mme Mérigot, La Cuisinière républicaine, qui enseigne la manière simple d'accommoder les pommes de terre; avec quelques avis sur les soins nécessaires pour les conserver Archived July 12, 2023, at the Wayback Machine, Paris, Chez Mérigot jeune, 1794–1795, 42 p. C. Monteros, J. Jiménez, Gavilanes, La Magia de la Papa Nativa. Recetario Gastronómico, Quito, INIAP, 2006, 71 p.
In 1995, Ice-T had a recurring role as vengeful drug dealer Danny Cort on the television series New York Undercover, co-created by Dick Wolf. His work on the series earned him the 1996 NAACP Image Award for Outstanding Supporting Actor in a Drama Series. In 1997, he co-created the short-lived series Players, produced by Wolf. This was followed by a role as pimp Seymour "Kingston" Stockton in Exiled: A Law & Order Movie (1998). These collaborations led Wolf to add Ice-T to the cast of Law & Order: Special Victims Unit. Since 2000, he has portrayed Odafin "Fin" Tutuola, a former undercover narcotics officer transferred to the Special Victims Unit. In 2002, the NAACP awarded Ice-T with a second Image Award, again for Outstanding Supporting Actor in a Drama Series, for his work on Law & Order: SVU. Around 1995, Ice-T co-presented a UK-produced magazine television series on black culture, Baadasss TV. In 1997, Ice-T had a pay-per-view special titled Ice-T's Extreme Babes which appeared on Action PPV, formerly owned by BET Networks. In 1999, Ice-T starred in the HBO film Stealth Fighter as a United States Naval Aviator who fakes his own death, steals an F-117 stealth fighter, and threatens to destroy United States military bases. He also acted in the film Sonic Impact, released the same year. Ice-T made an appearance on the comedy television series Chappelle's Show as himself presenting the award for "Player Hater of the Year" at the "Player-Haters Ball", a parody of his own appearance at the Players Ball. He was dubbed the "Original Player Hater".
Sources: en.wikipedia.org
Dihexa is a synthetic peptide investigated in preclinical research. It is often classified as an angiotensin IV analog or an HGF mimetic. It is not an approved medicine.
No. Regulatory agencies have not approved dihexa for human use. It is sold as a research chemical in some markets, and human safety and efficacy data are lacking.
Laboratory studies have examined its effects on synapse formation and cognitive tasks in animals. These are early-stage findings. They do not prove benefits or safety in people.
Dihexa is a synthetic peptide analog of angiotensin IV, often described as an HGF mimetic in research literature. It is studied for effects on synaptic connectivity in laboratory models. It is not an approved medication.